ProCE Banner Activity

Importance of Early Recognition and Management of Immune-Related Adverse Events to Optimize Outcomes With Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer and Other Malignancies

Clinical Thought

Commentary by an NP with extensive experience treating patients with immune checkpoint inhibitors (ICIs) about providing education for patients, caregivers, and the healthcare team to prevent, anticipiate, detect, and treat immune-related adverse events to maximize outcomes with ICIs. 

Released: November 29, 2022

Expiration: November 28, 2023

No longer available for credit.

Share

Faculty

Marianne Davies

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Provided by

ProCE Banner

Supporters

This activity is supported by

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Marianne Davies,DNP, ACNP, FAAN, has no relevant financial relationships to disclose.

Additional Information

Program Medium

This program has been made available online.